Get started
Author

Sandra Klein

Observed names: Klein, Sandra, S. Klein
OpenAlex ID: A5083235365
Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
2022 · Claire Harrison, Marina Kremyanskaya, et al. · Blood · 11
S198: Bet Inhibitor Pelabresib (cpi-0610) Combined With Ruxolitinib in Patients With Myelofibrosis — Jak Inhibitor-naïve or With Suboptimal Response to Ruxolitinib — Preliminary Data From the Manifest Study
2022 · J. Mascarenhas, M. Kremyanskaya, et al. · HemaSphere · 9
Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24
2022 · John Mascarenhas, Marina Kremyanskaya, et al. · Blood · 5
P1018: Updated Results From Manifest Arm 2: Efficacy and Safety of Pelabresib (cpi-0610) as Add-on to Ruxolitinib in Myelofibrosis
2023 · Marina Kremyanskaya, Claire Harrison, et al. · HemaSphere · 3
Pelabresib (CPI-0610) monotherapy in high-risk essential thrombocythemia refractory or intolerant to hydroxyurea: Preliminary results from MANIFEST study.
2023 · Francesco Passamonti, Andrea Patriarca, et al. · Journal of Clinical Oncology · 1
PDF
S168: Pelabresib (cpi-0610) Monotherapy in Patients With High-risk Essential Thrombocythemia Refractory or Intolerant to Hydroxyurea: Preliminary Results From Manifest Study
2023 · Francesco Passamonti, Andrea Patriarca, et al. · HemaSphere
P1027: Updated Durability of Response and Safety in Manifest Arm 3: Pelabresib (cpi-0610) Combined With Ruxolitinib for Jak Inhibitor Treatment-naïve Patients With Myelofibrosis
2023 · Claire Harrison, Andrea Patriarca, et al. · HemaSphere
Works count: 8
Citation count: 31
H-index: 3
I10-index: 1
Year
Topic
Type